Publications

  • Medina-Echeverz J, Vasquez M, Gomar C, Ardaiz N, Berraondo P. Overexpression of apolipoprotein A-I fused to an anti-transforming growth factor beta peptide modulates the tumorigenicity and immunogenicity of mouse colon cancer cells.Cancer Immunol Immunother. 2015 Jun;64(6):717-25. doi: 10.1007/s00262-015-1681-9. Epub 2015 Mar 21. PubMed PMID: 25795134.

  • Berraondo P, Di Scala M, Korolowicz K, Thampi LM, Otano I, Suarez L, Fioravanti J, Aranda F, Ardaiz N, Yang J, Kallakury BV, Tucker RD, Vasquez M, Menne S, Prieto J, González-Aseguinolaza G. Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I. J Hepatol. 2015 Aug;63(2):329-36. doi: 10.1016/j.jhep.2015.02.048. Epub 2015 Mar 12. PubMed PMID: 25772035; PubMed Central PMCID: PMC4508219.

  • Medina-Echeverz J, Aranda F, Berraondo P. Myeloid-derived cells are key targets of tumor immunotherapy. Oncoimmunology. 2014 Apr 15;3:e28398. eCollection 2014. Review. PubMed PMID: 25050208; PubMed Central PMCID: PMC4063142.

  • Medina-Echeverz J, Fioravanti J, Díaz-Valdés N, Frank K, Aranda F, Gomar C, Ardaiz N, Dotor J, Umansky V, Prieto J, Berraondo P. Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases. PLoS One. 2014 May 5;9(5):e96799. doi: 10.1371/journal.pone.0096799. eCollection 2014. PubMed PMID: 24797128; PubMed Central PMCID: PMC4010484.

  • Ochoa MC, Melero I, Berraondo P. High-density lipoproteins delivering interleukin-15. Oncoimmunology. 2013 Apr 1;2(4):e23410. PubMed PMID: 23734302; PubMed Central PMCID: PMC3654572.

  • Parra-Guillen ZP, Berraondo P, Grenier E, Ribba B, Troconiz IF. Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategies. AAPS J. 2013 Jul;15(3):797-807. doi: 10.1208/s12248-013-9483-5. Epub 2013 Apr 19. PubMed PMID: 23605806; PubMed Central PMCID: PMC3691429.

  • Ochoa MC, Fioravanti J, Duitman EH, Medina-Echeverz J, Palazon A, Arina A, Dubrot J, Alfaro C, Morales-Kastresana A, Murillo O, Hervas-Stubbs S, Prieto J, Berraondo P, Melero I. Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy. PLoS One. 2012;7(12):e52370. doi: 10.1371/journal.pone.0052370. Epub 2012 Dec 21. PubMed PMID: 23285013; PubMed Central PMCID: PMC3528770.

  • Medina-Echeverz J, Berraondo P. How can chemoimmunotherapy best be used for the treatment of colon cancer? Immunotherapy. 2012 Dec;4(12):1787-90. doi: 10.2217/imt.12.124. PubMed PMID: 23240744.

  • Ochoa MC, Mazzolini G, Hervas-Stubbs S, de Sanmamed MF, Berraondo P, Melero I. Interleukin-15 in gene therapy of cancer. Curr Gene Ther. 2013 Feb;13(1):15-30. Review. PubMed PMID: 23157547.

  • Ochoa MC, Fioravanti J, Rodriguez I, Hervas-Stubbs S, Azpilikueta A, Mazzolini G, Gúrpide A, Prieto J, Pardo J, Berraondo P, Melero I. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. Cancer Res. 2013 Jan 1;73(1):139-49. doi: 10.1158/0008-5472.CAN-12-2660. Epub 2012 Nov 13. PubMed PMID: 23149919.

  • Parra-Guillen ZP, Fioravanti J, Medina-Echeverz J, Gomar C, Ardaiz N, Troconiz IF, Berraondo P. Kinetic and dynamic computational model-based characterization of new proteins in mice: application to interferon alpha linked  to apolipoprotein A-I. PLoS One. 2012;7(7):e42100. doi: 10.1371/journal.pone.0042100. Epub 2012 Jul 27. PubMed PMID: 22848716; PubMed Central PMCID: PMC3407104.

  • Berraondo P, Umansky V, Melero I. Changing the tumor microenvironment: new strategies for immunotherapy. Cancer Res. 2012 Oct 15;72(20):5159-64. doi: 10.1158/0008-5472.CAN-12-1952. Epub 2012 Jul 23. PubMed PMID: 22826606.

  • Fioravanti J, Medina-Echeverz J, Ardaiz N, Gomar C, Parra-Guillén ZP, Prieto J, Berraondo P. The fusion protein of IFN-α and apolipoprotein A-I crosses the blood-brain barrier by a saturable transport mechanism. J Immunol. 2012 Apr 15;188(8):3988-92. doi: 10.4049/jimmunol.1101598. Epub 2012 Mar 14. PubMed PMID: 22422884.

  • Quetglas JI, Fioravanti J, Ardaiz N, Medina-Echeverz J, Baraibar I, Prieto J, Smerdou C, Berraondo P. A Semliki forest virus vector engineered to express IFNα induces efficient elimination of established tumors. Gene Ther. 2012 Mar;19(3):271-8. doi: 10.1038/gt.2011.99. Epub 2011 Jul 7. PubMed PMID: 21734727.

  • Fioravanti J, Gomar C, Medina-Echeverz J, Otano I, Benito A, Prieto J, González-Aseguinolaza G, Berraondo P. Characterization of woodchuck apolipoprotein A-I: a new tool for drug delivery and identification of altered isoforms in the woodchuck chronic hepatitis model. J Med Virol. 2011 Jul;83(7):1221-9. doi: 10.1002/jmv.22104. Epub 2011 Apr 22. PubMed PMID: 21520143.

  • Fioravanti J, González I, Medina-Echeverz J, Larrea E, Ardaiz N, González-Aseguinolaza G, Prieto J, Berraondo P. Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties. Hepatology. 2011 Jun;53(6):1864-73. doi: 10.1002/hep.24306. Epub 2011 May 2. PubMed PMID: 21425312.

  • Fioravanti J, Medina-Echeverz J, Berraondo P. Scavenger receptor class B, type I: a promising immunotherapy target. Immunotherapy. 2011 Mar;3(3):395-406. doi: 10.2217/imt.10.104. Review. PubMed PMID: 21395381.

  • Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol. 2011 Jan 15;186(2):807-15. doi: 10.4049/jimmunol.1001483. Epub 2010 Dec 8. PubMed PMID: 21148040.



"The identification of new targets to potentiate immune responses to cancer is the first step toward safer and more effective antitumor drugs", Dr. Pedro Berraondo.

More information:

Contact

Contact:
Cristina López
Avda. Pío XII, 55
31008 Pamplona
Spain

(+34) 948 194 700 Ext. 6021
clopezg@unav.es